Abstract: A manually operated back stretching device may relieve compressive forces of the lower lumbar vertebrae and may safely stretch lower back muscles. The device may include a platform to support a user's lower legs. As the user moves a portion of the device with their arms towards their legs, the forward edge of the platform may rise up and tilt away from the user's torso, causing the user's hips to lift off the floor and stretching the user's back at the same time. As the user moves their arms back over their head, the user's back and legs may relax while the arms are pulled above the user's head. The result may be a back-and-forth dynamic rotational arching motion to repetitively raise the completely relaxed hips and tilt them forward to decompress the spine using appropriate longitudinal and torsion forces at the most pain causing compression points of the lower lumbar vertebrae.

Abstract: A bedding design enables a user to fold a portion of the bedding underneath itself to create a pouch. The pouch may provide warmth for a user's feet and lower legs when they are lying in bed. The bedding may include a comforter with optional sheets and/or blankets. The additional sheets and/or blankets may be folded in a similar manner, either separately or together with the comforter. The comforter may be designed with an additional flap attached thereto so that folding the flap to create the pouch does not change the appearance of the bedding on a bed.

Abstract: Disclosed are novel pyrrole derivatives, a process for their manufacture, pharmaceutical compositions containing such compounds and the use of such compounds in the treatment of HIV mediated diseases.

Abstract: The present invention relates to compounds of the formula wherein R1 and R2 are as described within. The compounds of formula I have been found to be adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they may be used in the treatment of diseases, related to this receptor.

Abstract: The present invention relates to compounds of the formula wherein R1, R2 and R3 are as described herewithin. The compounds of formula I have been found to be adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they are therefore useful in the treatment of diseases, related to this receptor.

Abstract: The present invention relates to a medical device adhering to the skin comprising a housing with a rigid base fixable on a patient's skin by means of an adhesive layer which has an adhesive surface, essentially co-extensive with the base, contacting the skin and which is fixed to the base by a reduced surface in comparison to the adhesive surface contacting the skin.

Abstract: The present invention comprises nucleoside derivatives for use in the treatment or prophylaxis of hepatitis C virus infections. In particular, the present invention discloses the novel use of known 2′-deoxy-2′-fluoro nucleoside derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and pharmaceutical compositions of such compounds. The compounds of this invention have potential use as therapeutic agents for the treatment of HCV infections.

Abstract: The present invention is concerned with novel HIV protease Inhibitors of formula I as individual isomers, racemates, non-racemic mixtures or mixtures of diastereoisomers; wherein n, R1 and R4 are as described herein. The compounds of formula I are peptide mimetics which act as inhibitors of the HIV aspartyl protease, an essential enzyme in the replicative life cycle of HIV.

Abstract: Antibody binding to the SEMP1 antigen and characterized in that said antibody binds to SEMP1 in a manner equivalent to an antibody selected from the group of antibodies DSM ACC2458, DSM ACC2459, DSM ACC2461, and DSM ACC2463 is useful for cancer diagnosis and therapy.

Abstract: The present invention is a heteroaromatic substituted amide showing antagonist activity to neurokinin 1 (NK-1, substance P) receptors.

Abstract: The present invention relates to compounds of the formula wherein R1 and R2 are as defined herewithin. The compounds of formula I have been found to be adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they are therefore useful in the treatment of diseases, related to this receptor.

Abstract: The present invention relates to compounds of the formula wherein R1, A and R are as described within. The compounds of the present invention have been found to be adenosine receptor ligands. Specifically, the compounds of the present invention have an affinity to the A2A-receptor and are therefore useful in the treatment of diseases related to this receptor.

Abstract: The present invention is concerned with a novel process for the preparation of compounds of formula I comprising bromomethylation or chloromethylation of a compound of formula II and subsequent reaction with a compound of formula IV The compounds of formula I and the corresponding salts, e.g. the sodium salts, are pharmaceutically active substances.

Abstract: The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salt, solvate and ester thereof, wherein R1 to R4 and n are as defined in the specification. A compound of formula 1 is useful as a pharmaceutical composition for the treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.

Abstract: The present invention relates to compounds of the formula wherein R is as defined herewithin. The compounds of formula I have a good affinity to the A2A receptor and therefore they may be used in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or against asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, aniticonvulsants and cardiaprotective agents for disorders such as coronary artery disease and heart failure.

Abstract: A method and a needleless injection system for administering a medication. In order to simplify as far as possible the handling necessary for loading the injector with medication and thereby eliminate risks caused by a complex handling the method and system according to the invention provide loading of medication into a needleless injector device by means of a syringe prefilled with a medication, this loading step preferably including connecting the syringe to the injector device by means of a suitable coupling member or adapter and operating the syringe for transferring medication prefilled therein into the injector device. After this transfer the syringe and/or the coupling member or adapter are detached from the injector device, which is then ready to be operated for ejecting the loaded dosage of said medication from the injector device and thereby pass the selected dosage through the skin of an injection receiver.

Abstract: The present invention is a series of compounds formed from phenyl substituted pyridine or benzene derivatives and their pharmaceutically acceptable salts. These compounds have shown high affinity as antagonists to the NK-1 receptor.

Abstract: The present invention is a compound of formula: wherein R1, R2, R2′, X, A1/A2 and B are as defined in the specification. These compounds may be used in the control or prevention of acute and/or chronic neurological disorders such as restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycaemia, Alzheimer's disease, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, cognitive disorders, memory deficits, schizophrenia, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, acute and chronic pain, dyskinesia and depression.